{"id":9736,"date":"2020-04-02T11:32:08","date_gmt":"2020-04-02T19:32:08","guid":{"rendered":"https:\/\/drugpolicy.ca\/?p=9736"},"modified":"2020-04-19T09:26:42","modified_gmt":"2020-04-19T17:26:42","slug":"expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada","status":"publish","type":"post","link":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/","title":{"rendered":"Expanding access to diacetylmorphine &#038; hydromorphone in Canada"},"content":{"rendered":"\n<iframe loading=\"lazy\" class=\"scribd_iframe_embed\" title=\"Maghsoudi2020 Article ExpandingAccessToDiacetylmorph\" src=\"https:\/\/www.scribd.com\/embeds\/454652304\/content?start_page=1&amp;view_mode=scroll&amp;access_key=key-0A2BcI0fedCQ1S5Pved0\" data-auto-height=\"false\" data-aspect-ratio=\"0.75\" scrolling=\"no\" id=\"doc_60531\" width=\"100%\" height=\"600\" frameborder=\"0\"><\/iframe>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-background is-style-dots\" style=\"background-color:#ffffff;color:#ffffff\"\/>\n\n\n\n<div class=\"wp-block-buttons aligncenter is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background\" href=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Maghsoudi2020_Article_ExpandingAccessToDiacetylmorph.pdf\" style=\"background-color:#c42127\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF<\/a><\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><p style=\"margin-top:30px; text-align:center\"><strong>Click <a href=\"https:\/\/drugpolicy.ca\/covid-19-harm-reduction-resources\/\" target=\"_blank\" rel=\"noreferrer noopener\">HERE<\/a> for more resources<\/strong><\/p><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Abstract: <\/strong>The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine\/naloxone and methadone are the standard first-line of opioid substitution options, limitations, including difficulty achieving long-term retention for some people who use opioids, are well known. For this group, injectable diacetylmorphine or hydromorphone can achieve positive outcomes, including high retention rates, reduced use of unregulated opioids, and reduced criminal activity. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In May 2019, Health Canada announced changes to increase the accessibility of diacetylmorphine and hydromorphone, and in September 2019, the CIHR-funded Canadian Research Initiative in Substance Misuse released a national clinical guideline for diacetylmorphine and hydromorphone as additional frontline substitution options. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While these developments present opportunities for scale-up, significant financial, structural, and practice barriers continue to impede access. This commentary explores the current state of policy and practice for diacetylmorphine and hydromorphone as opioid substitution options in Canada, outlines the rationale for rapid expansion of access, and highlights clinical and policy changes that must be undertaken or the death toll will continue to rise.<\/p>\n\n\n\n<div class=\"widget signup-widget mb-5\">\r\n<p class=\"lead\"><strong>\u00cates-vous pr\u00eat(e) \u00e0 aider ?<\/strong><\/p>\r\n<p>Soutenez des politiques sur les drogues bas\u00e9es sur la justice sociale, la compassion et les preuves. Inscrivez-vous \u00e0 notre newsletter pour obtenir des mises \u00e0 jour et d\u00e9couvrez comment vous pouvez agir avec nous.<\/p>\r\n<!-- form.123formbuilder.com script begins here --><script type=\"text\/javascript\" defer=\"defer\" src=\"https:\/\/form.123formbuilder.com\/embed\/6415583.js\" data-role=\"form\" data-default-width=\"650px\"><\/script><!-- form.123formbuilder.com script ends here -->\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"<p>Click HERE for more resources Abstract: The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine\/naloxone and methadone are the standard first-line of opioid substitution options, limitations, including difficulty achieving long-term retention for some people who use opioids, are well known. For this group, injectable diacetylmorphine or hydromorphone can [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":9746,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"categories":[1120],"tags":[1124],"class_list":["post-9736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-research","tag-safe-supply-oat-and-ioat"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Expanding access to diacetylmorphine &amp; hydromorphone in Canada - Canadian Drug Policy Coalition<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Expanding access to diacetylmorphine &amp; hydromorphone in Canada - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"Click HERE for more resources Abstract: The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine\/naloxone and methadone are the standard first-line of opioid substitution options, limitations, including difficulty achieving long-term retention for some people who use opioids, are well known. For this group, injectable diacetylmorphine or hydromorphone can [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-02T19:32:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-19T17:26:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"811\" \/>\n\t<meta property=\"og:image:height\" content=\"551\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canadian Drug Policy Coalition\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/\"},\"author\":{\"name\":\"Canadian Drug Policy Coalition\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\"},\"headline\":\"Expanding access to diacetylmorphine &#038; hydromorphone in Canada\",\"datePublished\":\"2020-04-02T19:32:08+00:00\",\"dateModified\":\"2020-04-19T17:26:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/\"},\"wordCount\":183,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Screen-Shot-2020-04-02-at-12.20.07-PM.png\",\"keywords\":[\"safe supply OAT and iOAT\"],\"articleSection\":[\"covid research\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/\",\"name\":\"Expanding access to diacetylmorphine & hydromorphone in Canada - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Screen-Shot-2020-04-02-at-12.20.07-PM.png\",\"datePublished\":\"2020-04-02T19:32:08+00:00\",\"dateModified\":\"2020-04-19T17:26:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#primaryimage\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Screen-Shot-2020-04-02-at-12.20.07-PM.png\",\"contentUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/Screen-Shot-2020-04-02-at-12.20.07-PM.png\",\"width\":811,\"height\":551},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Expanding access to diacetylmorphine &#038; hydromorphone in Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\",\"name\":\"Canadian Drug Policy Coalition\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"caption\":\"Canadian Drug Policy Coalition\"},\"description\":\"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/author\\\/canadian-drug-policy-coalition\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Expanding access to diacetylmorphine & hydromorphone in Canada - Canadian Drug Policy Coalition","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/","og_locale":"fr_FR","og_type":"article","og_title":"Expanding access to diacetylmorphine & hydromorphone in Canada - Canadian Drug Policy Coalition","og_description":"Click HERE for more resources Abstract: The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine\/naloxone and methadone are the standard first-line of opioid substitution options, limitations, including difficulty achieving long-term retention for some people who use opioids, are well known. For this group, injectable diacetylmorphine or hydromorphone can [&hellip;]","og_url":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/","og_site_name":"Canadian Drug Policy Coalition","article_published_time":"2020-04-02T19:32:08+00:00","article_modified_time":"2020-04-19T17:26:42+00:00","og_image":[{"width":811,"height":551,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png","type":"image\/png"}],"author":"Canadian Drug Policy Coalition","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Canadian Drug Policy Coalition","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#article","isPartOf":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/"},"author":{"name":"Canadian Drug Policy Coalition","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30"},"headline":"Expanding access to diacetylmorphine &#038; hydromorphone in Canada","datePublished":"2020-04-02T19:32:08+00:00","dateModified":"2020-04-19T17:26:42+00:00","mainEntityOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/"},"wordCount":183,"publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png","keywords":["safe supply OAT and iOAT"],"articleSection":["covid research"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/","url":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/","name":"Expanding access to diacetylmorphine & hydromorphone in Canada - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#primaryimage"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png","datePublished":"2020-04-02T19:32:08+00:00","dateModified":"2020-04-19T17:26:42+00:00","breadcrumb":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#primaryimage","url":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png","contentUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/04\/Screen-Shot-2020-04-02-at-12.20.07-PM.png","width":811,"height":551},{"@type":"BreadcrumbList","@id":"https:\/\/new.drugpolicy.ca\/fr\/expanding-access-to-diacetylmorphine-and-hydromorphone-for-people-who-use-opioids-in-canada\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Expanding access to diacetylmorphine &#038; hydromorphone in Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.drugpolicy.ca\/fr\/#website","url":"https:\/\/www.drugpolicy.ca\/fr\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drugpolicy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/www.drugpolicy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30","name":"Canadian Drug Policy Coalition","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","caption":"Canadian Drug Policy Coalition"},"description":"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice","url":"https:\/\/new.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/"}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=9736"}],"version-history":[{"count":16,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9736\/revisions"}],"predecessor-version":[{"id":10067,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9736\/revisions\/10067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/9746"}],"wp:attachment":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=9736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/categories?post=9736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/tags?post=9736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}